US equities |
SPCX $168.50 ▲+6.00% NVDA $237.31 ▲+1.44% MU $1,066.28 ▼-0.80% TSLA $378.72 ▲+2.19% MSFT $525.43 ▲+1.53% SNDK $1,714.20 ▼-0.34% INTC $117.22 ▼-1.76% META $742.92 ▲+2.04%
FinancialContent

Relmada Therapeutics, Inc. - Common Stock (NQ:RLMD)

3.470 -0.130 (-3.61%)
Delayed Quote Updated: 1:14 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relmada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024 ↗
RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023 ↗
RLMD stock results show that Relmada Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Recap: Relmada Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 19, 2024 ↗
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million. 
Via Benzinga
News headline image
Earnings Outlook For Relmada Therapeutics ↗
 
Via Benzinga
News headline image
Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying ↗
The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Topics Stocks
News headline image
Earnings Outlook For Relmada Therapeutics ↗
 
Via Benzinga
News headline image
Relmada Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.< 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study ↗
Relmada Therapeutics Inc (NASDAQ: RLMD) announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3... 
Via Benzinga
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says ↗
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick ↗
For investors who choose wisely, profits in healthcare stocks can be spectacular. But the losses can also be dramatic if you choose poorly. 
Via InvestorPlace
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Seagate, Chegg, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Relmada, DoubleVerify, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Seagate, Chegg, and Relmada and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Bowlero, and Integra and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Investor Alert: Investigation Concerning Potential Securities Laws Violations ↗
San Diego, CA -- (SBWIRE) -- 05/11/2023 -- An investigation was announced for investors of Relmada Therapeutics, Inc. (NASDAQ:RLMD) shares over potential securities laws violations by Relmada... 
Via SBWire
< Previous 1 2 3 4 5 6 Next >